Get the Stockscreener App
9.2505
5.17%
0.4505
Overview
News
Price History
Option Chain
Why GRFS Down?
Discussions
Forecast
Stock Split
Dividend History
Grifols Sa Adr stock is traded at $9.2505, with a volume of 807.67K.
It is up +5.17% in the last 24 hours and up +3.76% over the past month.
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.
See More
Previous Close:
$8.80
Open:
$8.74
24h Volume:
807.67K
Relative Volume:
0.73
Market Cap:
$5.98B
Revenue:
$7.42B
Net Income/Loss:
$182.73M
P/E Ratio:
32.08
EPS:
0.2884
Net Cash Flow:
$709.16M
1W Performance:
+12.87%
1M Performance:
+3.76%
6M Performance:
+40.87%
1Y Performance:
-0.59%
1-Day Range:
$8.6943
$9.38
1-Week Range:
$8.38
$9.38
52-Week Range:
$5.3001
$12.15
Grifols Sa Adr Stock (GRFS) Company Profile
Name
Grifols Sa Adr
Sector
Industry
Phone
-
Address
-
Grifols Sa Adr Stock (GRFS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-12-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-03-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-16-23 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-18-23 | Upgrade | Jefferies | Hold → Buy |
| Apr-08-22 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-05-21 | Downgrade | Deutsche Bank | Buy → Hold |
| Oct-19-21 | Downgrade | Barclays | Overweight → Underweight |
| Oct-06-21 | Upgrade | Citigroup | Neutral → Buy |
| Jun-14-21 | Upgrade | Deutsche Bank | Hold → Buy |
| Apr-20-21 | Initiated | Deutsche Bank | Hold |
| Mar-23-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Mar-11-21 | Upgrade | HSBC Securities | Hold → Buy |
| Oct-01-20 | Upgrade | Citigroup | Sell → Neutral |
| Jun-09-20 | Downgrade | Citigroup | Neutral → Sell |
| Jun-09-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Mar-25-20 | Downgrade | Citigroup | Buy → Neutral |
| Jun-27-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Feb-08-19 | Downgrade | Berenberg | Buy → Hold |
| Oct-11-18 | Upgrade | Berenberg | Hold → Buy |
| Jun-01-18 | Initiated | Barclays | Overweight |
| Oct-31-17 | Initiated | Citigroup | Buy |
| Jun-30-17 | Downgrade | Goldman | Buy → Neutral |
| Apr-06-17 | Initiated | BofA/Merrill | Buy |
| Jan-03-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Feb-09-16 | Upgrade | Berenberg | Hold → Buy |
| Jan-04-16 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Dec-02-15 | Downgrade | HSBC Securities | Buy → Hold |
| Nov-20-15 | Downgrade | Berenberg | Buy → Hold |
| Apr-28-15 | Downgrade | Berenberg | Buy → Hold |
View All
Grifols Sa Adr Stock (GRFS) Latest News
Infectious Disease Diagnostics Market to Reach USD 43.09 Billion by 2031 | SkyQuest Technology - Benzinga
Is it possible to buy Grifols SA ADR(GRFS) shares at a good price now? - US Post News
Grifols SA ADR (GRFS)’s Day in Review: Closing at 8.58, Down by -0.12 - The Dwinnex
RFID Kanban Systems Market Forecast to Reach $9.53 Billion by 2030 - GlobeNewswire Inc.
A Look at Grifols SA ADR (GRFS) Shares in the Recent Past Indicates Growth - SETE News
Cboe Global Markets Inc. (AMEX: CBOE): Getting A Free Pass? - Stocks Register
It is Poised to be a Bull Market for Grifols SA ADR (GRFS) - SETE News
Grifols: Here Is Why It's Still A 'Buy' Even If Price Goes Down (NASDAQ:GRFS) - Seeking Alpha
Examining Grifols SA ADR (GRFS) stock is warranted - US Post News
Are Grifols SA ADR’shares a good deal? - US Post News
Financial Health Report: Grifols SA ADR (GRFS)’s Ratios Tell a Tale - The Dwinnex
Was anything negative for Grifols SA ADR (GRFS) stock last session? - US Post News
Ratio Review: Analyzing Grifols SA ADR (GRFS)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
GRFS’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle
How does Grifols SA ADR (GRFS) change from a tortoise to a hare? - SETE News
Mexico Blood Transfusion Diagnostics Market Size & Outlook, 2027 - Grand View Research
The Significance of Moving Averages in Grifols SA ADR Inc. (GRFS) Price Performance - The InvestChronicle
Have you been able to find a good deal on Grifols SA ADR’s shares? - US Post News
Closing Figures: Grifols SA ADR (GRFS)’s Negative Finish at 8.41, Down -1.87 - The Dwinnex
A History of Outperforming Analyst Forecasts and Beating the Odds: Grifols SA ADR (GRFS) - SETE News
Analytical Overview: Grifols SA ADR (GRFS)’s Ratios Tell a Financial Story - The Dwinnex
Investing in Grifols SA ADR (GRFS) might be an excellent idea, but the stock is currently overvalued/undervalued - US Post News
Grifols Class B stock falls as Brookfield reportedly seeks lower price - MSN
Grifols Class B stock discounted by Brookfield (NASDAQ:GRFS) - Seeking Alpha
An analyst sees good growth prospects for Grifols SA ADR (GRFS) - SETE News
Grifols SA ADR [GRFS] Is Currently 1.11 below its 200 Period Moving Avg: What Does This Mean? - The DBT News
Grifols SA ADR (GRFS)’s Market Momentum: Closing Strong at 9.00, Up 2.74 - The Dwinnex
Grifols SA ADR (GRFS) looking to reclaim success with recent performance - SETE News
Why Grifols (GRFS) Stock Price Moved Up 7% on Wednesday - Yahoo Finance
Is the Grifols SA ADR (NASDAQ:GRFS) stock an investment opportunity? - US Post News
Get in on Grifols SA ADR’s (GRFS) buy-in window today! - SETE News
Grofols stock gains as Brookfield eyes takeover (NASDAQ:GRFS) - Seeking Alpha
Market Update: Grifols SA ADR (GRFS) Sees Positive Movement, Closing at 7.18 - The Dwinnex
XPeng Inc. Sponsored ADR (XPEV) Laps the Stock Market: Here's Why - Yahoo Finance
How did Grifols SA ADR (GRFS) fare last session? - US Post News
Ratios Revealed: Decoding Grifols SA ADR (GRFS)’s Financial Health - The Dwinnex
Grifols SA ADR: A Comprehensive Look at the Stock’s Ups and Downs - The InvestChronicle
Are Investors Inclined To Sell Their Bath & Body Works Inc (NYSE: BBWI) Holdings? - Stocks Register
Does Uranium Royalty Corp (NASDAQ: UROY) Still Need To Convince Analysts? - Stocks Register
What Do Wall Street Analysts Think About Tetra Technologies, Inc. (NYSE: TTI) Stock? - Stocks Register
What Did We Find About Insider Trading At Monster Beverage Corp. (NASDAQ: MNST)? - Stocks Register
The growth track for Grifols SA ADR (GRFS) has changed recently - SETE News
India Blood Transfusion Diagnostics Market Size & Outlook, 2027 - Grand View Research
Investing in Grifols SA ADR (GRFS) might be a great opportunity, but the stock is a bit overvalued - US Post News
Validea Joseph Piotroski Strategy Daily Upgrade Report8/6/2024 - Nasdaq
Grifols SA ADR’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - The InvestChronicle
Our Attention Has Been Attracted to Grifols SA ADR (NASDAQ:GRFS) - US Post News
Grifols revises past financial records with equity value drop of $494 mln - Marketscreener.com
Grifols SA ADR (GRFS) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
You might want to take a look at Grifols SA ADR (GRFS) now - SETE News
A stock that deserves closer examination: Grifols SA ADR (GRFS) - US Post News
Grifols Sa Adr Stock (GRFS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.13%
0.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):